KRAS and non-small cell lung carcinoma: In a large cohort of patients with KRAS-mutated NSCLC, mutations in TP53 (39.4%), STK11 (19.8%), KEAP1 (12.9%), ATM (11.9%), MET (15.4%), and HER2 amplifications (13.8%), only few rare co-occurring targetable mutations were found in EGFR (1.2%) and BRAF (1.2%) genes [85].